دورية أكاديمية
أعرض في EDS

New panel of biomarkers to discriminate between amelanotic and melanotic metastatic melanoma.

التفاصيل البيبلوغرافية
العنوان: New panel of biomarkers to discriminate between amelanotic and melanotic metastatic melanoma.
المؤلفون: Militaru IV; Department of Molecular Cell Biology, Institute of Biochemistry, Bucharest, Romania., Rus AA; Department of Molecular Cell Biology, Institute of Biochemistry, Bucharest, Romania., Munteanu CVA; Department of Bioinformatics and Structural Biochemistry, Institute of Biochemistry, Bucharest, Romania., Manica G; Department of Molecular Cell Biology, Institute of Biochemistry, Bucharest, Romania., Petrescu SM; Department of Molecular Cell Biology, Institute of Biochemistry, Bucharest, Romania.
المصدر: Frontiers in oncology [Front Oncol] 2023 Jan 26; Vol. 12, pp. 1061832. Date of Electronic Publication: 2023 Jan 26 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مستخلص: Melanoma is a form of skin cancer that can rapidly invade distant organs. A distinctive feature of melanomas is their pigmentation status, as melanin is present in most skin melanomas, whilst many metastatic tumors could become amelanotic. Besides the obvious malfunction of the key genes of the melanin pathway, the amelanotic tumors could bear a characteristic molecular signature accounting for their aggressivity. Using mass spectrometry-based proteomics we report here a distinctive panel of biomarkers for amelanotic aggressive melanoma that differ from the less invasive pigmented cells. The developed method allows the label-free quantification of proteins identified by LC-MS/MS analysis. We found a set of proteins comprising AHNAK, MYOF, ANXA1, CAPN2, ASPH, EPHA2, THBS1, TGM2, ACTN4 along with proteins involved in cell adhesion/migration (integrins, PLEC, FSCN1, FN1) that are highly expressed in amelanotic melanoma. Accompanying the down regulation of pigmentation specific proteins such as tyrosinase and TYRP1, these biomarkers are highly specific for a type of highly invasive melanoma. Interestingly, the LC-MS/MS proteomics analysis in hypoxia revealed that the abundance of this specific set of proteins found in normoxia was rather unaltered in these conditions. These biomarkers could therefore predict a metastatic behaviour for the amelanotic cells in the early stages of the tumor development and thus serve in melanoma prognostic. Applying this algorithm to related databases including melanoma samples published by independent laboratories/public databases we confirm the specificity of the newly found signatures. Overall, we begin to unravel the molecular alterations in the amelanotic melanoma and how basic proteomics offers insights into how to assess the clinical, pathological and misdiagnosis differences between the main subtypes of melanoma.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Militaru, Rus, Munteanu, Manica and Petrescu.)
References: Oncotarget. 2017 Apr 11;8(15):25395-25417. (PMID: 28445987)
J Clin Invest. 2009 Jun;119(6):1429-37. (PMID: 19487819)
Bioinformatics. 2016 Sep 15;32(18):2847-9. (PMID: 27207943)
Cancer Res. 2018 Jan 1;78(1):216-229. (PMID: 29093007)
Cancer Res. 2004 Aug 1;64(15):5270-82. (PMID: 15289333)
Br J Cancer. 2018 Sep;119(6):713-723. (PMID: 30116025)
Melanoma Res. 2015 Dec;25(6):496-502. (PMID: 26317170)
Pigment Cell Melanoma Res. 2015 Jul;28(4):464-75. (PMID: 25950383)
Nat Rev Mol Cell Biol. 2007 Oct;8(10):786-97. (PMID: 17878918)
J Natl Cancer Inst. 2009 Sep 16;101(18):1259-71. (PMID: 19704071)
J Clin Oncol. 2002 May 15;20(10):2530-6. (PMID: 12011132)
PLoS One. 2015 Jun 10;10(6):e0129219. (PMID: 26061439)
Biochemistry. 2000 May 9;39(18):5229-37. (PMID: 10819991)
J Proteome Res. 2014 Nov 7;13(11):5031-40. (PMID: 25322343)
Cancer Res. 2010 May 1;70(9):3780-90. (PMID: 20388789)
J Biol Chem. 2004 Feb 27;279(9):7971-81. (PMID: 14634018)
Cancers (Basel). 2020 Jan 11;12(1):. (PMID: 31940801)
Pigment Cell Res. 2006 Aug;19(4):290-302. (PMID: 16827748)
Elife. 2021 Jan 13;10:. (PMID: 33438577)
J Biomol Tech. 2018 Jul;29(2):25-38. (PMID: 29805321)
Hum Pathol. 2001 Sep;32(9):945-53. (PMID: 11567224)
Cancer Res. 2008 Feb 1;68(3):650-6. (PMID: 18245463)
Oncotarget. 2016 Apr 5;7(14):17844-53. (PMID: 26910282)
J Am Acad Dermatol. 2019 May;80(5):1292-1298. (PMID: 30654075)
Oncogene. 2009 Jul 30;28(30):2697-709. (PMID: 19483722)
J Biol Chem. 2007 Sep 21;282(38):27557-61. (PMID: 17635904)
J Invest Dermatol. 1977 Jun;68(6):369-78. (PMID: 405430)
Nat Biotechnol. 2008 Dec;26(12):1367-72. (PMID: 19029910)
Mol Biol Cell. 2010 Oct 1;21(19):3362-75. (PMID: 20702585)
PLoS One. 2011;6(7):e21908. (PMID: 21747967)
J Immunol. 1998 Feb 15;160(4):1750-8. (PMID: 9469433)
J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1174-81. (PMID: 21175876)
Int J Oncol. 2018 Apr;52(4):1071-1080. (PMID: 29532857)
Cancer Cell. 2004 Dec;6(6):565-76. (PMID: 15607961)
J Biol Chem. 2003 Jul 18;278(29):27035-42. (PMID: 12719423)
J Pathol. 2003 Jul;200(4):448-64. (PMID: 12845612)
Fundam Clin Pharmacol. 2020 Feb;34(1):20-31. (PMID: 31410885)
Adv Cancer Res. 2010;109:73-121. (PMID: 21070915)
Genes Dev. 2006 Dec 15;20(24):3426-39. (PMID: 17182868)
Sci Rep. 2017 May 4;7(1):1498. (PMID: 28473727)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Br J Exp Pathol. 1983 Feb;64(1):103-15. (PMID: 6838761)
Cell. 2018 Apr 5;173(2):400-416.e11. (PMID: 29625055)
Cancer Cell. 2018 May 14;33(5):890-904.e5. (PMID: 29657129)
JAMA Dermatol. 2014 Dec;150(12):1306-314. (PMID: 25162299)
Int J Mol Sci. 2021 Feb 22;22(4):. (PMID: 33671632)
J Biol Chem. 1997 Jun 20;272(25):15796-803. (PMID: 9188477)
Arch Dermatol. 2006 Dec;142(12):1551-8. (PMID: 17178980)
Exp Cell Res. 2008 Nov 15;314(19):3570-80. (PMID: 18848541)
Database (Oxford). 2016 Jul 03;2016:. (PMID: 27374120)
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. (PMID: 34723319)
Cell. 2020 Jan 23;180(2):387-402.e16. (PMID: 31978347)
Cells. 2020 May 07;9(5):. (PMID: 32392801)
Neoplasia. 2017 Jan;19(1):17-27. (PMID: 27987437)
Nat Methods. 2016 Sep;13(9):731-40. (PMID: 27348712)
Diagnostics (Basel). 2021 Jul 26;11(8):. (PMID: 34441278)
Mol Cell. 2018 Nov 1;72(3):444-456.e7. (PMID: 30401431)
Cancers (Basel). 2021 Apr 22;13(9):. (PMID: 33922182)
Pigment Cell Res. 1994 Dec;7(6):419-27. (PMID: 7761350)
J Proteome Res. 2010 Jul 2;9(7):3656-63. (PMID: 20459140)
Sci Rep. 2017 Aug 18;7(1):8864. (PMID: 28821754)
Adv Exp Med Biol. 2019;1140:155-167. (PMID: 31347047)
Cancer Res. 2003 Oct 15;63(20):6716-25. (PMID: 14583466)
Int J Mol Sci. 2020 May 14;21(10):. (PMID: 32423001)
Hum Pathol. 2013 Oct;44(10):2071-4. (PMID: 23791398)
Neoplasia. 2021 Nov;23(11):1147-1165. (PMID: 34706306)
PLoS One. 2013;8(2):e56420. (PMID: 23409183)
Pharmaceutics. 2021 Dec 10;13(12):. (PMID: 34959411)
Sci Rep. 2019 Jun 26;9(1):9280. (PMID: 31243305)
Sci Rep. 2018 Sep 26;8(1):14379. (PMID: 30258109)
فهرسة مساهمة: Keywords: amelanotic melanoma; mass spectrometry; melanoma biomarkers; melanoma diagnostic; melanoma prognostic; proteomics
تواريخ الأحداث: Date Created: 20230213 Latest Revision: 20230214
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9909407
DOI: 10.3389/fonc.2022.1061832
PMID: 36776379
قاعدة البيانات: MEDLINE
الوصف
تدمد:2234-943X
DOI:10.3389/fonc.2022.1061832